Sermorelin research: what the trials measured, graded before the verdict

In plain English

This page collects the sermorelin studies. The short story: in children who could not make enough growth hormone, daily sermorelin sped up growth; in healthy older men, it pushed an age-faded GH/IGF-1 system back toward youthful numbers for two weeks. The peptide leaves the blood in about ten minutes, but the growth-hormone bump it causes lasts a few hours. The strongest evidence is decades old and is about children; the adult anti-aging story is thinner, and the studies say so. Below, every claim is tied to a named, dated paper.

Sermorelin acetate: the salt form studied

Sermorelin acetate is the form used in the literature — the GHRH(1-29) peptide prepared as its acetate salt, supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions degrade ^[1]. The acetate salt has its own identifiers (CAS 114466-38-5) distinct from the free peptide, and reconstituted material is typically refrigerated. This is the substance behind every figure on this page; "sermorelin" and "sermorelin acetate" refer to the same molecule in its salt form.

The GHRH-receptor cascade

Sermorelin's activity runs through one receptor and one signaling chain — the sermorelin mechanism of action set out in summary on the home page. It binds the GHRH receptor on anterior-pituitary somatotrophs, engaging the Gs / adenylate cyclase / cAMP / protein kinase A pathway, which raises cyclic AMP and drives both GH gene transcription and GH release ^[1]. Over time the receptor signaling also has a trophic effect — it supports the somatotroph cell population itself.

The loop stays closed. Somatostatin and IGF-1 feedback remain intact, and GH autofeedback on the GHRH response — involving free fatty acids and somatostatin — has been demonstrated directly in humans ^[13]. This is why sermorelin produces pulsatile rather than continuous GH, and why pulsatile GHRH delivery preserved the GH response better than continuous infusion in normal men ^[12].

Sermorelin half-life and pharmacokinetics

The sermorelin half-life is short. After intravenous administration, GHRH(1-29)NH2 is cleared from plasma on the order of 10-12 minutes ^[3]. In 30 healthy men, intravenous doses elicited GH release from as little as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg; despite the rapid clearance, serum growth hormone stayed elevated for about 3 hours after a single dose ^[3]. By the intranasal route, bioavailability was only about 3-5% — a figure that explains why oral and sublingual "sermorelin" products are widely criticized in research-user communities as ineffective, since peptides are degraded in the gut and absorbed poorly across mucosa ^[3].

The brevity of the native fragment is the reason longer-acting analogs exist. Incorporating D-Ala2 into GHRH(1-29)NH2 increased its half-life and decreased its metabolic clearance in normal men ^[7] — the structure-activity step that leads to the DAC-based analogs on the sermorelin vs CJC-1295 page.

Does sermorelin work? What the trials show

Does sermorelin work? In its best-evidenced setting, yes. In prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth, lifting first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, and it did so without excessive IGF-1 generation ^[1].

In aging research the signal is also real but narrower. In healthy older men (mean 68 years), 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after high-dose treatment, their GH/IGF-1 parameters no longer differed from those of young men, with no effect on fasting glucose ^[2]. The downstream IGF-1 effect can be sizeable: in the SMART trial of a stabilized GHRH analog, IGF-1 rose by 117% within the physiologic range ^[6].

What "work" does not yet mean is a proven long-term adult anti-aging or body-composition benefit. Those outcomes are documented mainly for the related analog tesamorelin, and authorities have cautioned against extrapolating ^[5].

The GH/IGF-1 axis in aging and the brain

The most striking recent data come from the GHRH-analog class as a whole. In a randomized, double-blind, placebo-controlled trial of 152 older adults — 66 of them with mild cognitive impairment — 20 weeks of a daily GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition (P=0.03), with the strongest signal in executive function (P=0.005), alongside a 117% IGF-1 rise and a 7.4% reduction in percent body fat ^[6].

This is the GH/IGF-1 axis in aging studied directly: raising GH and IGF-1 through a GHRH analog produced measurable cognitive and body-composition changes in older adults. It is the clearest evidence that the axis sermorelin engages is biologically active in aging humans — while remaining a finding about tesamorelin, not a license to claim the same magnitude for sermorelin itself.

Reported side effects in the sermorelin literature

Sermorelin side effects reported in the trial literature were generally mild — injection-site reactions are the most common, and the older-men study found no change in fasting glucose ^[2]. Adverse events in the SMART trial of the related analog were likewise mild ^[6].

The honest caveats are about scope, not acute toxicity. Long-term safety data specifically for adult anti-aging use are limited, and the Annals editorial judged secretagogue use for aging "not yet ready for prime time" ^[5]. Because GH and IGF-1 are mitogenic, chronically elevating them is theorized to carry an oncologic consideration — a recognized point for any GH-axis intervention, even one that works through the body's own feedback-regulated pulsatile secretion. This site describes these findings; it gives no dosing instructions and makes no recommendation to self-administer.

Sermorelin and testosterone: what the research does and does not show

On sermorelin testosterone questions the literature is clear by what it omits. Sermorelin acts on the GH/IGF-1 somatotropic axis — the pituitary's growth-hormone cells — not on the hypothalamic-pituitary-gonadal axis that governs testosterone ^[1]. The published studies document GH and IGF-1 changes ^[2][3][6]; they do not report testosterone effects. Claims that sermorelin raises testosterone are therefore not supported by the GHRH(1-29) trial record presented here, and this brief frames the two axes as distinct rather than implying a crossover the data does not show.

Regulatory and anti-doping status

The regulatory history is often misstated, so state it precisely. Sermorelin was an FDA-approved prescription drug for the evaluation and treatment of growth hormone deficiency / short stature in children, and it was withdrawn from the US market in 2008 for commercial reasons — not for safety or efficacy problems. It is not a currently-marketed approved finished drug; it is now prepared by compounding pharmacies and treated as a long-standing Category 1 bulk drug substance under FDA's Section 503A framework, with final guidance in January 2025. It is not a controlled substance under the Controlled Substances Act.

In sport, growth hormone secretagogues — including GHRH and its analogs — are prohibited by WADA under hormone and metabolic modulators (S2), and dedicated detection methods for GHRH analogs exist. The material discussed here is research-grade sermorelin supplied for laboratory study, not a compounded prescription or a finished medicine.